At the post-transcriptional level, the well-established role of MDM2 as the major regulator of p53, in partnership with MDM4, is being elaborated to define therapeutic relevance (reviewed in53) and the oncogenic role of these regulators in mutant p53 cancers is also being exposed (for example,54). The gene discussed is MDM2; the disease is cancer.